Vertex Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
CEOReshma Kewalramani
CEOReshma Kewalramani
Employees6,100
Employees6,100
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded1989
Founded1989
Employees6,100
Employees6,100
VRTX Key Statistics
Market cap118.07B
Market cap118.07B
Price-Earnings ratio-118.10
Price-Earnings ratio-118.10
Dividend yield—
Dividend yield—
Average volume1.01M
Average volume1.01M
High today$469.96
High today$469.96
Low today$458.14
Low today$458.14
Open price$466.10
Open price$466.10
Volume975.04K
Volume975.04K
52 Week high$519.88
52 Week high$519.88
52 Week low$377.85
52 Week low$377.85
VRTX News
TipRanks 2d
Cautious Hold Rating on Vertex Pharmaceuticals Amid Efficacy UncertaintyAnalyst Mohit Bansal of Wells Fargo maintained a Hold rating on Vertex Pharmaceuticals, retaining the price target of $460.00. Elevate Your Investing Strategy:...
Simply Wall St 3d
Vertex Pharmaceuticals Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatmentexperienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimburs...
Simply Wall St 4d
Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated ValueOver the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 1...
Analyst ratings
54%
of 35 ratingsBuy
54.3%
Hold
40%
Sell
5.7%
More VRTX News
TipRanks 5d
Vertex Pharmaceuticals price target raised to $517 from $515 at JPMorganJPMorgan raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $517 from $515 and keeps an Overweight rating on the shares. The firm adjusted the c...
People also own
Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.